Vanda Pharmaceuticals Inc. (VNDA) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

FanaptHetlioz
08M15M22M30M38M45M52M60MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Revenue by Geography

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
025M50M75M100M125M150M175M200MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Margin (%)

Gross MarginOperating MarginNet Income Margin
0255075100125150175200Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Operating Expenses

Research And Development ExpensesSelling General And Administrative ExpensesOther Expenses
025M50M75M100M125M150M175M200MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

EBITDA

EBITDA
-40M-35M-30M-25M-20M-15M-10M-5M1Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

EPS

Revenue Variation (%)

Revenue Variation
-7-4-03610131720Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Income Variation (%)

Gross Profit VariationOperating Income VariationNet Income Variation
01252503755006257508751KQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Revenue YoY Variation (%)

Revenue YoY Variation
048111519222630Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY VariationNet Income YoY Variation
02505007501K1K2K2K2KQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Price-to-Earning Ratio

P/E Ratio
-20-17-15-12-10-7-4-21Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Income Breakdown

Operating IncomeTotal Other Income Expenses NetNet Income
01M2M3M4M6M7M8M9MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Per Share Metrics

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
000111222Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Expense Ratios

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
000001111Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
💰 Cash Flow Statement

Operating Cash Flow

Free Cash Flow

Cash At End Of Period
025M50M75M100M125M150M175M200MQ3 2024Q4 2024Q1 2025Q2 2025

Cash Flow to Debt Ratio

🏦 Balance Sheet
📈 Key Metrics